Maintenance of response in moderate-to-severe psoriasis after withdrawal of the interleukin (IL)-17A and IL-17F nanobody sonelokimab: is there a role for IL-17F in disease reoccurrence?
Kristian Reich, Eva Cullen, Mark Weinberg
Abstract
Abstract
Topics & Concepts
PsoriasisMedicineInterleukin 17DiseaseInterleukinInterleukin 2ImmunologyCytokineInternal medicinePsoriasis: Treatment and PathogenesisImmunodeficiency and Autoimmune DisordersAsthma and respiratory diseases